Background. This study aimed to determine whether type and duration of therapy for human immunodeficiency virus (HIV) infection attenuates liver fibrosis in patients with HIV and hepatitis C virus (HCV) coinfection.
), compared with group 1. P ! .0001 P ! .006 Conclusions. HIC-HCV-coinfected subjects who receive HAART as their sole form of therapy have liver histology findings comparable to those for HCV-monoinfected patients. A similar degree of benefit is not observed for HIV-HCV-coinfected patients who receive no therapy, NRTIs, or HAART after NRTIs, despite having a longer duration of therapy.
The advent of HAART has significantly improved survival rates among patients with HIV infection [1] . Increasing attention is now being focused on coinfection with other viruses, such as hepatitis C virus (HCV). Because of similar routes of transmission, ∼25%-30% of patients with HIV infection are also coinfected with HCV. In some high-risk groups (e.g., hemophiliacs and injection drug users), the prevalence may be higher (70%-80%) [2, 3] . The immunosuppression induced by HIV accelerates the natural history of HCV-related liver disease, and HIV-HCV-coinfected subjects are 2-3-fold more likely to develop cirrhosis than are HCVmonoinfected patients [4, 5] . Also, because of improved survival rates among HIV-infected persons, studies indicate that liver-related mortality now accounts for up to 40%-50% of all deaths among HIV-HCV-coinfected patients [6, 7] . However, many of these studies were conducted before the introduction of HAART.
In fact, recently published data have suggested that there has been a reduction in liver-related mortality among HIV/HCV-coinfected patients who have received HAART, although little information was provided about liver histologic findings [8, 9] . The few studies that have addressed the effects of HIV therapy on HCV-related liver fibrosis were not controlled and produced conflicting results [10] [11] [12] [13] [14] [15] . Furthermore, there is ongoing concern regarding potential hepatotoxicity associated with HAART, especially for drugs such as nevirapine [14, 16, 17] . Therefore, the aim of this study was to address impact of type and duration of antiretroviral therapy on the severity of HCV-related liver disease in HIV-HCV-coinfected subjects.
PATIENTS, MATERIALS, AND METHODS
The study period was 1994-2004. All patients were retrospectively recruited from the Los Angeles County Hepatitis and HIV/HCV clinics by reviewing patient cards and charts. To be eligible for the study the subject had to be HCV positive (as determined by qualitative PCR), to have undergone a liver biopsy, and to have complete clinical data available.
All liver biopsy specimens were assessed by either of 2 hepatopathologists (S.G. and G.K.), and findings were expressed on the basis of the modified histological activity index (necroinflammatory score of 0-18 and fibrosis stage of 0-6) of Ishak et al. [18] . Estimated fibrosis progression was calculated by dividing the fibrosis stage at the time of the index liver biopsy by the estimated disease duration [19] .
HCV antibody status was determined using the HCV-EIA 2.0 (Abbott Laboratories). Qualitative PCR analysis for HCV was performed by nested PCR (in-house method), with a lower limit of detection of 10 copies/mL. Quantitative HCV analysis (available from October 1999) was initially assessed using the Cobas Amplicor HCV Monitor v2.0 (Roche Molecular Systems) and was subsequently assessed using the TaqMan HCV Test (Focus Laboratories). HCV genotyping was performed using a line-probe assay (INNO-LiPA HCV II; Immunogenetics). HIV load was assessed using the Amplicor HIV Monitor-1 test (Roche Molecular Systems).
Therapy for HIV was classified as follows: antiretroviral therapy was classified as use of any nucleoside reverse-transcriptase inhibitor (NRTI), and HAART was classified as use of any 2 NRTIs with any protease inhibitor (PI) or nonnucleoside reverse-transcriptase inhibitor (NNRTI). HAART was introduced in the HIV clinic in 1996. Patients with HCV monoinfection (group 1) and HIV-HCV coinfection were retrospectively selected; the latter patients were classified into the following 3 groups: group 2, patients who received no therapy or only nucleoside reverse-transcriptase inhibitors (NRTIs); group 3, those who received HAART (also called "the HAART-only group"); and group 4, those who initially received NRTIs but whose therapy was changed to HAART after 1996 (also called "the sequential therapy group").
Our aim was to calculate the total duration of HIV therapy before liver biopsy was performed. If therapy was interrupted for any length of time, we subtracted that time from the total treatment duration. Alcohol abuse was defined as consumption of у40 g of alcohol per day. Stepwise multiple logistic regression analysis was performed to determine independent predictors of fibrosis stage. Survival curves were generated using the Kaplan Meier estimates, to determine probability of developing cirrhosis, and differences between groups were analyzed by the log rank test. The statistical software program used was StatView, version 5.1, and SPSS, version 8.2 (SPSS).
RESULTS
During the period 1994-2004, there were 381 patients who were HCV positive (determined by qualitative PCR) and who had undergone a liver biopsy with an adequate sample available for histological analysis. Two hundred ninety-six patients were HCV monoinfected (group 1), and 85 were HIV-HCV coinfected.
The mean age at HIV diagnosis was years, and 37.2 ‫ע‬ 9.8 the mean CD4 cell count was cells/mm 3 . Forty-270.1 ‫ע‬ 255.4 three (50%) of 85 patients had a CD4 cell count of р200 cells/ mm 3 at the time of diagnosis. Of the 85 HIV-HCV-coinfected patients, 25 (29%) had received either no HIV therapy (n p ) or had received only antiretroviral therapy ( ; group 9 n p 16 2). Twenty-two patients (26%) had received only HAART (group 3), because their HIV was diagnosed after 1996, and 38 patients (45%) had received sequential therapy (i.e., they initially received antiretroviral therapy and switched to HAART after 1996; group 4). Thus, groups 2-4 represented cohorts treated (or not) according to the availability of drugs. The mean durations of antiretroviral therapy (for group 2), HAART (for group 3), and sequential therapy (for group 4) before liver biopsy was performed were , , and 3.8 ‫ע‬ 2.8 3.3 ‫ע‬ 1.8 6.6 ‫ע‬ years, respectively. Group 4 patients had received antiret-2.2 roviral therapy for years, followed by years 2.7 ‫ע‬ 1.1 3.9 ‫ע‬ 1.8 of HAART, before biopsy was performed. Of the 60 patients who had received HAART (i.e., groups 3 and 4), 25 received a PI (7 both a PI and an NNRTI at different time intervals (7 patients in group 3 and 14 patients in group 4; ). Nine patients P p NS had received nevirapine (4 patients in group 3 and 5 patients in group 4) for a mean duration of years before 2.5 ‫ע‬ 0.8 undergoing biopsy. All patients who received a PI or an NNRTI did so as part of HAART-that is, no patient received a PI or an NNRTI as monotherapy.
Abnormal liver test results occurred for 9 patients (11%) after the introduction of HIV therapy. Three patients developed lactic acidosis (!3-fold elevation in transaminase levels), 1 developed indirect hyperbilirubinemia after receiving atazanavir, 2 developed a !3-fold elevation in transaminase levels after receiving PI therapy, and 3 had reversible liver injury with receipt of nevirapine (у5-fold elevation in bilirubin level and/ or у5-fold elevation in transaminase levels). Table 1 shows the data at study entry for HCV-monoinfected and HIV-HCV-coinfected patients. The median HCV load was significantly higher for the 64 HIV-HCV-coinfected patients with available data than for the 216 HCV-monoinfected subjects ( IU/mL [range, to IU/mL] ). Although the prevalence of male subjects was P p .01 higher in the HIV-HCV-coinfected group, there were no statistically significant sex-related differences in fibrosis stage (4.2 vs. 3.9) or fibrosis progression (0.20 vs. 0.19 per year) for male and female subjects, respectively. All HIV-HCV-coinfected patients who were positive for hepatitis B surface antigen (but none of the patients from group 1) were receiving lamivudine. Only one of the patients with chronic hepatitis B virus infection was positive for hepatitis B antigen e. Table 2 shows data for the HIV-HCV-coinfected cohort (i.e., groups 2-4) at time of biopsy. The groups were well matched with regard to age at liver biopsy, prevalence of alcohol abuse, obesity, and diabetes mellitus. At baseline, HIV-related parameters were similar as well. At the time of biopsy, group 3 patients were most likely to achieve increase in the CD4 cell count to у100 cells/mm 3 ). At time of P p NS liver biopsy, the HIV load was also lower in group 3 than in groups 2 and 4.
Overall, patients in group 3 (i.e., the HAART-only group) had less advanced liver fibrosis than did patients in groups 2 and 4. In fact, HCV-related disease severity in HCV-monoin- fected patients (group 1) was similar to that in group 3 patients, as determined on the basis of fibrosis stage (mean, 3.1 vs. 3.4), fibrosis progression (mean, 0.13 vs. 0.16 per year), necroinflammatory score (mean, 6.1 vs. 6.1), and prevalence of cirrhosis (mean, 32% vs. 41%). Age at biopsy was similar in groups 1 and 3, although the prevalence of hepatitis B virus coinfection was significantly higher in group 3 (mean, 14% vs. 5%; P ! ). Patients in groups 2 and 4, however, had a more-ad-.0006 vanced fibrosis stage ( ), faster fibrosis progression P ! .0009 ( ), higher necroinflammatory score ( com-P ! .0001 P ! .0001 pared with group 2, and (not significant) compared P p .3 with group 4), and greater prevalence of cirrhosis ( ), P ! .006 compared with HCV-monoinfected patients.
When patients in group 2 were further stratified into those who had received no treatment and those who had received only antiretroviral therapy, both subgroups had significantly more-advanced liver disease, compared with HCV-monoinfected patients and patients in the HAART-only group (data not shown). When patients were classified into PI recipients and NNRTI recipients, no significant differences were observed (table 3) . However, we performed additional analysis of groups 3 and 4 after excluding patients who had received nevirapine. Group Figure 1 shows the estimated mean time from HCV exposure to the biopsy that revealed cirrhosis in the 4 groups. The times were similar for groups 1 and 3 ( ), although groups 2 P p .3 ( ) and 4 ( ) had significantly shorter times to P ! .0001 P p .009 cirrhosis than did HCV-monoinfected subjects. Group 3 patients also took a longer time to develop cirrhosis, compared with patients in group 2 ( ). Figure 2 shows the prob-P p .07 ability of developing cirrhosis (Kaplan Meir survival curves) for the 4 groups. After 25 years of HCV exposure, the probability of developing cirrhosis in group 1 was 16%, compared with 24% in group 3 (
) and 72% and 38% in groups P p .02 2 and 4, respectively ( ). The probability of developing P ! .0001 cirrhosis was also lower in group 3 than in group 2 ( ). P p .01 for group 1 vs. groups 2 and 4; for group 1 vs. group 3. P values were determined by log rank test. P ! .001 P p .02 Table 4 shows the characteristics of HIV-HCV-coinfected patients categorized by a fibrosis stage of у4 or !4 at the index biopsy. Factors that were significant on univariate analysis ( ) were then entered in a stepwise fashion into a logistic P р .05 regression model. Independent predictors of a fibrosis score of у4 in HIV-HCV-coinfected patients were necroinflammatory score at index liver biopsy (OR, 1.5; 95% CI, 1.1-2.0; P p ), alcohol abuse (OR, 7.6; 95% CI, 2.3-25.4; ), .008 P p .0009 and duration of alcohol abuse (OR, 1.2; 95% CI, 1-1.4; P p ) (table 4) . .02
DISCUSSION
This study has shown that HIV-HCV-coinfected subjects who had received a diagnosis of HIV infection after 1996-and, therefore, who received HAART as the sole form of therapy (for a mean of 3.3 years)-had similar necroinflammatory scores, fibrosis stages, rates of fibrosis progression, and prevalences and mean times to cirrhosis development as those for the HCV-monoinfected population. The probability of developing cirrhosis was numerically higher but not too dissimilar (16% vs. 24%). Overall, HAART recipients had less severe fibrosis than did those receiving no drugs, antiretroviral therapy, or antiretroviral therapy sequentially followed by HAART. Although subjects in group 4 had also received HAART, a similar degree of benefit was not observed, probably because of the delay between the diagnosis of HIV infection (mean duration of delay, 31 months) and HAART initiation. Although 11% of the patients did develop some form of HAART-associated liver injury, in no cases was it life threatening, and it resulted in no long-term adverse consequences, even in nevirapine recipients.
The effects of HIV therapy on HCV-related liver fibrosis in HIV-HCV-coinfected subjects are controversial. Tural et al. [15] did not find that PI therapy (mean duration, 12 months) was protective against liver fibrosis. Similarly, Sterling et al. [11] and Mehta et al. [20] found no difference in hepatic fibrosis among persons who were administered or not administered PIs or NNRTIs. We also did not find attenuation of HCV-related liver disease when our patients were classified into those who had received a PI and those who had received an NNRTI (table  3) . However, Benhamou et al. [12] observed that use of PI for a median of 14 months did, in fact, attenuate liver fibrosis in a coinfected cohort (fibrosis stage, 1.69 vs. 2.10;
). These P p .03 conflicting results are not surprising, because the study populations had different ethnicities (predominantly white in the study by Benhamou et al. [12] , African American in the studies by Sterling et al. [11] and Mehta et al. [20] , and Hispanic in this study), age at biopsy (almost a decade younger in Benhamou and colleagues' study), prevalence of alcohol abuse (as low as 20%), and variable severity of HIV disease at presentation (in Sterling and colleagues' study, 11% of subjects had a CD4 cell count of !200 cells/mm it was unclear whether patients who received HAART did so as the sole form of therapy (comparable to our group 3) or had received NNRTIs initially and subsequently had their regimens switched to HAART after 1996 (as in our group 4). In fact, in the study by Mehta et al. [20] , no benefit of HAART was observed, despite administration of 3 years of therapy. If these patients were akin to our group 4 subjects, the results are not surprising. We actually observed more HCV-related benefits in group 3 than in group 4, although the duration of HAART was longer in the latter group (3.9 vs. 3.3 years). This may be because group 4 patients had a significantly longer time from diagnosis of HIV infection to HAART initiation, compared with group 3 (34.1 vs. 9.1 months; ). This suggests that it P ! .0001 is not just the presence or duration of HAART, but the promptness with which it is initiated after HIV diagnosis that favorably impacts hepatic fibrosis. A recent French study supports this hypothesis: the duration between presumed HCV exposure and HAART initiation was significantly longer for patients with severe fibrosis than for those with no fibrosis or moderate fibrosis [21] .
Two prospective studies have already documented decreased liver-associated mortality in HIV-HCV-coinfected patients who have received HAART [8, 9] . The mechanisms by which HAART confers protection against progression of HCV-related liver disease are complex. In our study, at the time of the liver biopsy, patients in group 3 had higher CD4 cell counts and lower HIV loads, compared with patients in the other groups. They were also most likely to achieve an increase in the CD4 cell count of у100 cells/mm 3 while receiving therapy. The same was true for patients who had a fibrosis score of у4, compared with those who had a score of !4, suggesting that immune restoration may play an important role. A recent study published in abstract form suggests that suppressing the HIV load helps slow the progression of liver fibrosis; this is consistent with our findings [22] . Another plausible explanation is immune restoration-induced change in intrahepatic cytokine release, which could reduce hepatic fibrosis [12] .
The necroinflammatory score at the time of the index biopsy was also lower in group 3 patients; in addition, it was an independent predictor of developing stage у4 fibrosis. In fact, the necroinflammatory score for group 3 subjects was comparable to that for HCV-monoinfected subjects. Mehta et al. [20] also observed lower necroinflammatory scores among patients who had received HAART for longer durations. It is conceivable, therefore, that if HAART is initiated promptly after the diagnosis of HIV infection (as opposed to only NRTI treatment or NRTI followed by HAART), there is a more pronounced decrease in necroinflammatory activity, which, in the medium to long term, translates into less severe hepatic fibrosis.
Although, in this study, we observed both immunological and hepatic benefits with HAART, the current recommendations are to not initiate HAART for patients with a CD4 cell count of 1350 cells/mm 3 and an HIV load of !100,000 copies/ mL [23] . Furthermore, in presence of HCV coinfection, it may be preferable to treat the HCV infection first, before HAART initiation. This strategy reduces the risks of antiretroviral-induced adverse effects (both hepatotoxicity and additive toxicity [mitochondrial and psychiatric]) and may improve the degree of immune restoration once HAART is started [24, 25] . Also, according to the RIBAVIC study, for patients infected with HCV genotypes other than genotype 1, the absence of PI therapy is an independent predictor of sustained virological response to IFN-based therapy [26] .
Inherent to its retrospective nature, this study did have limitations. Second, we only reported on a single rate of liver fibrosis. The HIV-HCV-coinfected patients may actually have had 2 different rates, depending on when HIV infection was acquired in relation to HCV infection. However, because ∼70% of our HIV-HCV-infected cohort had history of injection drug use, we can assume that most subjects had been infected with HCV years before acquiring HIV infection [27] . Finally, the sample size of the HIV-HCV-coinfected subjects was small, and our results need to be validated by larger prospective studies.
In conclusion, it is not just the presence or duration of HAART, but the timing of its initiation that positively influences the course of liver fibrosis in HIV-HCV-infected subjects. The patients most likely to benefit are those who had HIV infection diagnosed after 1996 and, therefore, received only HAART, rather than NRTIs alone or NRTIs sequentially followed by HAART. This attenuation of HCV-related liver disease appears to be chiefly related to immune restoration after HAART introduction, as evidenced by the more robust CD4 cell count recovery in group 3. Along with reducing the severity of liver fibrosis and necroinflammation, HAART also appears to have an excellent hepatic safety profile. However, in presence of wellpreserved CD4 cell counts, it would be advisable to treat HCV infection first.
